Ocrelizumab may leads to lower number of participants with new or enlarging T2‐hyperintense lesions… compared with interferon beta‐1a (low certainty).
Sunitinib probably leads to lower progression‐free survival (absolute effect size estimates based on… compared with interferon‐α (IFN‐α) (targeted agent versus classic immunotherapy) (moderate certainty).
Sunitinib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with interferon‐α (IFN‐α) (targeted agent versus classic immunotherapy) (low certainty).
Sunitinib probably leads to higher serious adverse events (Grade 3 or 4)assessed as: CTCAE v3.0 compared with interferon‐α (IFN‐α) (targeted agent versus classic immunotherapy) (moderate certainty).
Fingolimod 0.5 mg showed no clear difference in withdrawals due to adverse events compared with interferon beta‐1a (moderate certainty).
Fingolimod 0.5 mg probably leads to lower annualised relapse rate compared with interferon beta‐1a (moderate certainty).
Fingolimod 0.5 mg probably leads to higher participants free from MRI gadolinium‐enhancing lesions compared with interferon beta‐1a (moderate certainty).
The review found no eligible studies for this question.
Fingolimod 0.5 mg probably leads to higher participants free from relapse compared with interferon beta‐1a (moderate certainty).
Fingolimod 0.5 mg showed no clear difference in participants free from disability worsening compared with interferon beta‐1a (low certainty).
It is very uncertain whether intravesically administered BCG combined with IFN‐α changes recurrence compared with intravesically administered BCG alone (very low certainty).
The review found no eligible studies for this question.
Intravesically administered BCG combined with IFN‐α showed no clear difference in progression compared with intravesically administered BCG alone (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether intravesically administered BCG combined with IFN‐α changes disease‐specific mortality compared with intravesically administered BCG alone (very low certainty).
The review found no eligible studies for this question.
Intravesically administered BCG alternating with IFN‐α may leads to higher time‐to‐recurrence compared with intravesically administered BCG alone (low certainty).
Intravesically administered BCG alternating with IFN‐α showed no clear difference in time‐to‐progression compared with intravesically administered BCG alone (low certainty).
Intravesically administered BCG alternating with IFN‐α showed no clear difference in discontinuation of therapy due to adverse events compared with intravesically administered BCG alone (low certainty).